Hyperechogenicity of the Substantia Nigra in Parkinson’s Disease: Insights from Two Brothers with Markedly Different Disease Durations

Table 1

Demographical and clinical characteristics.

	Patient 1	Patient 2
Age (years)	60	59
Time since diagnosis (years)	19	9
LED (mg/day)	500	625
H&Y	2	2
MDS-UPRDS total	44	19
MDS-UPDRS part III	34	12
MMSE	30	30
BDI-II	1	6
RBDQ	5	3
Area of SN echogenicity (cm^2)	,	,
Diameter of third ventricle (cm)	0.65	0.31

H&Y: Hoehn and Yahr Clinical staging; MDS-UPDRS: Movement Disorder Society-Unified Parkinson’s Disease Rating Scale; LED: Levodopa equivalent dose; MMSE: Mini Mental State Examination; BDI-II: Beck Depression Inventory-II; RBDQ: REM Sleep Behaviour Disorder Questionnaire.